Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers

BackgroundGlucocorticoid replacement is essential in patients with primary and secondary adrenal insufficiency, but many patients remain on higher than recommended dose regimens. There is no uniformly accepted method to monitor the dose in individual patients. We have compared cortisol concentrations in plasma, saliva and urine achieved following “physiological” and “stress” doses of hydrocortisone as potential methods for monitoring glucocorticoid replacement.MethodsCortisol profiles were measured in plasma, saliva and urine following “physiological” (20 mg oral) or “stress” (50 mg intravenous) doses of hydrocortisone in dexamethasone-suppressed healthy subjects (8 in each group), compared to endogenous cortisol levels (12 subjects). Total plasma cortisol was measured half-hourly, and salivary cortisol and urinary cortisol:creatinine ratio were measured hourly from time 0 (between 0830 and 0900) to 5 h. Endogenous plasma corticosteroid-binding globulin (CBG) levels were measured at time 0 and 5 h, and hourly from time 0 to 5 h following administration of oral or intravenous hydrocortisone. Plasma free cortisol was calculated using Coolens’ equation.ResultsPlasma, salivary and urine cortisol at 2 h after oral hydrocortisone gave a good indication of peak cortisol concentrations, which were uniformly supraphysiological. Intravenous hydrocortisone administration achieved very high 30 minute cortisol concentrations. Total plasma cortisol correlated significantly with both saliva and urine cortisol after oral and intravenous hydrocortisone (P <0.0001, correlation coefficient between 0.61 and 0.94). There was no difference in CBG levels across the sampling period.ConclusionsAn oral dose of hydrocortisone 20 mg is supraphysiological for routine maintenance, while stress doses above 50 mg 6-hourly would rarely be necessary in managing acute illness. Salivary cortisol and urinary cortisol:creatinine ratio may provide useful alternatives to plasma cortisol measurements to monitor replacement doses in hypoadrenal patients.

[1]  A. Iranmanesh,et al.  Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. , 1993, The Journal of clinical endocrinology and metabolism.

[2]  G. Besser,et al.  Endocrine and metabolic diseases. Adrenal diseases. , 1976, British medical journal.

[3]  J. Ratcliffe,et al.  PATTERNS OF PLASMA CORTISOL AND ACTH CONCENTRATIONS IN PATIENTS WITH ADDISON'S DISEASE TREATED WITH CONVENTIONAL CORTICOSTEROID REPLACEMENT , 1981, Clinical endocrinology.

[4]  Jayne Holme,et al.  An evaluation of measured and calculated serum free cortisol in a group of patients with known adrenal suppression , 2010, Annals of clinical biochemistry.

[5]  W. Inder,et al.  Management of adrenal insufficiency during the stress of medical illness and surgery , 2008, The Medical journal of Australia.

[6]  R. Dullaart,et al.  The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. , 1998, The Journal of clinical endocrinology and metabolism.

[7]  H. Kehlet,et al.  GLUCOCORTICOID MAINTENANCE THERAPY FOLLOWING ADRENALECTOMY: ASSESSMENT OF DOSAGE AND PREPARATION , 1976, Clinical endocrinology.

[8]  W. Burch.  Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states. , 1982, JAMA.

[9]  S. Tunn,et al.  Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. , 1992, Clinical chemistry.

[10]  R. Eastell,et al.  Glucocorticoid replacement therapy: are patients over treated and does it matter? , 1997, Clinical endocrinology.

[11]  M. Debono,et al.  Modified-release hydrocortisone to provide circadian cortisol profiles. , 2009, The Journal of clinical endocrinology and metabolism.

[12]  L. Behan,et al.  Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin‐deficient hypopituitary male patients , 2011, Clinical endocrinology.

[13]  S. Lightman,et al.  Why is the management of glucocorticoid deficiency still controversial: a review of the literature , 2005, Clinical endocrinology.

[14]  M. Mclean,et al.  Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients , 2004, Clinical endocrinology.

[15]  S. Aanderud,et al.  Plasma cortisol concentrations after oral substitution of cortisone in the fasting and non-fasting state. , 2009, Acta medica Scandinavica.

[16]  V. Wright,et al.  Endocrine disorders , 1991, Current opinion in rheumatology.

[17]  M. J. Chapman,et al.  Septic shock and sepsis: a comparison of total and free plasma cortisol levels. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  Zaki K Hassan-Smith,et al.  11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess , 2014, Proceedings of the National Academy of Sciences.

[19]  D. Freedman,et al.  Evidence for the Low Dose Dexamethasone Suppression Test to Screen for Cushing's Syndrome—Recommendations for a Protocol for Biochemistry Laboratories , 1997, Annals of clinical biochemistry.

[20]  G. Tucker,et al.  Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia , 2006, Clinical endocrinology.

[21]  M. Zwahlen,et al.  Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. , 2012, The Journal of clinical endocrinology and metabolism.

[22]  J. Puder,et al.  Cortisol response in relation to the severity of stress and illness. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  G. Tucker,et al.  Modified‐release hydrocortisone for circadian therapy: a proof‐of‐principle study in dexamethasone‐suppressed normal volunteers , 2008, Clinical endocrinology.

[24]  R. Clayton,et al.  ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[25]  D. Scott.  Chapter 10 – Endocrine and Metabolic Diseases , 2001 .

[26]  E. Aardal,et al.  Cortisol in Saliva - Reference Ranges and Relation to Cortisol in Serum , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[27]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[28]  T. Howlett.  An Assessment of Optimal Hydrocortisone Replacement Therapy , 1997, Clinical endocrinology.

[29]  J. Connell,et al.  Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to Patients with adrenal insufficiency , 2007, Clinical endocrinology.

[30]  G. R. Cannell,et al.  Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. , 1984, British journal of clinical pharmacology.

[31]  M. Mclean,et al.  The clinical utility of alternative, less invasive sampling techniques in the assessment of oral hydrocortisone therapy in children and adolescents with hypopituitarism. , 2007, European journal of endocrinology.

[32]  C. Migeon,et al.  Cortisol production rate. II. Normal infants, children, and adults. , 1966, Pediatrics.

[33]  K. Løvås,et al.  Saliva cortisol measurement: Simple and reliable assessment of the glucocorticoid replacement therapy in Addison’s disease , 2006, Journal of endocrinological investigation.

[34]  E. Lentjes,et al.  Salivary Cortisol day curves in assessing glucocorticoid replacement therapy in Addison’s disease , 2013, Hormones.

[35]  Kristian Løvås,et al.  Continuous subcutaneous hydrocortisone infusion in Addison's disease. , 2007, European journal of endocrinology.

[36]  S. Hahner,et al.  Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements , 2006, Clinical endocrinology.

[37]  T. Hedner,et al.  Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. , 2009, European journal of endocrinology.

[38]  S. Lightman,et al.  Subcutaneous pulsatile glucocorticoid replacement therapy , 2014, Clinical endocrinology.

[39]  R. Carey,et al.  Adrenal insufficiency. , 1997, Current therapy in endocrinology and metabolism.

[40]  J L Coolens,et al.  Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. , 1987, Journal of steroid biochemistry.

[41]  A. Yergey,et al.  Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. , 1991, The Journal of clinical endocrinology and metabolism.

[42]  A. Rostami-Hodjegan,et al.  Weight‐related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency , 2004, Clinical endocrinology.

[43]  B. Arafah.  Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. , 2006, The Journal of clinical endocrinology and metabolism.

[44]  M. Debono,et al.  Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. , 2009, European journal of endocrinology.

[45]  R. Murray,et al.  European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy , 2014, BMC Endocrine Disorders.